Massimo Zucchetti


Ontology type: schema:Person     


Person Info

NAME

Massimo

SURNAME

Zucchetti

Publications in SciGraph latest 50 shown

  • 2017-06 Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-06 High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation in PHARMACEUTICAL RESEARCH
  • 2016-12 Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging in SCIENTIFIC REPORTS
  • 2016-12 3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors in SCIENTIFIC REPORTS
  • 2016-03 Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-01 Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer in BRITISH JOURNAL OF CANCER
  • 2014-08 Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2013-10 Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-10 In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-09 Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-05 Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-01 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2009-02 Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2007-10 Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel in BRITISH JOURNAL OF CANCER
  • 2006-09 Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2004-01 Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2004-01 Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2003-08 Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2003-03 IDN 5390: an oral taxane candidate for protracted treatment schedules in BRITISH JOURNAL OF CANCER
  • 2000-05 The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2000-02 Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin in BRITISH JOURNAL OF CANCER
  • 1999-09 Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1999-06 Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1999-02 Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1998-02 cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 1996-12 Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days in INVESTIGATIONAL NEW DRUGS
  • 1996-09 Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1995-07 Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833 in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1993-11 A limited sampling model for the pharmacokinetics of etoposide given orally in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1993 Pharmacokinetics of Anticancer Agents in Patients with Impaired Liver Function in DRUGS AND THE LIVER: HIGH RISK PATIENTS AND TRANSPLANTATION
  • 1992-11 Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1992-07 Do anticancer agents reach the tumor target in the human brain? in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1990-11 Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1988-07 Lack of effect of cisplatin on i. v. L-PAM plasma pharmacokinetics in ovarian cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1984-10 Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.4527.4", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415065.3", 
            "type": "Organization"
          }
        ], 
        "familyName": "Zucchetti", 
        "givenName": "Massimo", 
        "id": "sg:person.0720105551.12", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0002-5427-052X"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720105551.12", 
          "https://orcid.org/0000-0002-5427-052X"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:05", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_772.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0720105551.12'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0720105551.12'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0720105551.12'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0720105551.12'


     




    Preview window. Press ESC to close (or click here)


    ...